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Abstract 
The supplementary protection certificate is currently considered to represent an accessory of a national or 
European patent granted in order to extend the duration of the rights that said patent confers on its owner in 
respect of an active substance or a combination of active substances. Based on the above-mentioned patent and 
on the certificate, the owner shall have the exclusive right of manufacturing and commercializing the patented 
product, as well as the right to oppose to any form of counterfeiting of the patented product. The grant of this 
protection title for medicaments is regulated on the territory of the European Union by the Regulation (EC) 
No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary 
protection certificate for medicinal products (Codified version). The conditions for obtaining the certificate are 
stipulated under Art. 3. The paper is intended to present the decisions made by the Romanian courts in the cases 
concerning the controversial interpretation of Art. 3 letter d) of the Regulation, which provides that the valid 
authorization to place the medicament on the market in accordance with Directive 2001/83/EC or Directive 
2001/82/EC, as the case may be, should be the first authorization to place the product on the market as a 
medicament. At the same time, the paper presents the differences in the approach and the judgment of such cases 
by OSIM (State Office for Inventions and Trademarks) and by the national courts. The paper aims at analyzing 
said decisions as compared to the European practice, with a view to identifying solutions for a uniform 
interpretation of Community legislation at the level of the Romanian courts. 
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Introduction 
The supplementary protection certificate is currently seen rather as a patent sub-domain, than 
as an independent industrial property title. It is an accessory of a previously granted national or 
European patent, intended to extend the duration of the rights that said patent confers on its owner in 
respect of an active substance or a combination of active substances. Based on the above-mentioned 
patent, the owner shall have the exclusive right of manufacturing and commercializing the patented 
product, as well as the right to oppose to any form of counterfeiting of the patented product. 
 
In a field so dynamic as the field of medicaments and the industrial property rights of patent 
owners in medicaments within the EU, the Council Regulation (EEC) No. 1768/1992 on the creation 
of a supplementary protection certificate for medicaments
1, hereinafter referred to as Regulation, 
created the legal framework for the settlement of cases in which a pharmaceutical company that 
owns a patent for a medicament and is also authorized to place said medicament on the market, can 
enjoy the extension of duration of its exclusive rights by the grant of a supplementary protection 
certificate. 
                                                 
∗ Director Patents Directorate, State Office for Inventions and Trademarks, Romania, (email: 
bucura.ionescu@osim.ro). 
1 Council Regulation (EEC) of 18 June 1992 concerning the creation of a supplementary protection certificate 
for medicinal products (OJ L 182, p.1, Special edition 13, volume 11, p.130) Bucura Ionescu 1133 
The Regulation entered into force on 2 January 1993 and, in 2009, as a consequence of the 
evolution of exigencies in the pharmaceutical field, on the one hand, and of the changes occurred in 
the geopolitical area of the Community, on the other hand, the codified version thereof was adopted 
as the Regulation (EC) No 469/2009
2. In the following pages, reference will be made especially to 
the Regulation of 1992 and, where appropriate, the Regulation of 2009 will be called by the phrase 
“codified version”. 
Although the supplementary protection certificate was established in the Community almost 
20 years ago, specialized literature in this field can scarcely be found in Europe, Romania not even 
having judicial practice. 
The paper presents five decisions made by Romanian courts in disputes related to the 
controversial interpretation of Article 3 (d)
3 of the Regulation which provides that the valid 
authorization for placing a medicament on the market in accordance with the Directive 65/65/EEC 
should be the first authorization to place the product on the market as a medicinal product. The paper 
points out the different approaches and ruling of these five identically similar cases by the national 
protection granting authority - OSIM
4, and by the national courts. The paper aims at analyzing said 
decisions in the context of the European practice, with a view to identifying solutions for the uniform 
interpretation of Community legislation in Romanian courts. 
 
Content 
1.  Case Insulin lispro (the medicament named “Humalog”). File No. 42590/3/2009, Law 
Court of Bucharest, Fifth Civil Section 
The supplementary protection certificate application no. c2007-061 of the applicant Eli Lilly 
and Company, for the product having the chemical name Human insulin [Lys(B28), Pro(B29)] and 
the ICD Insulin lispro, was filed with OSIM on 20.06.2007, within the 6-month legal time limit of 
Romania’s accession to the European Union, under the transitional provisions stipulated in Article 
19a (l) of the Regulation
5. 
With a view to granting the SPC applied for, the Examination Board of OSIM analyzed the 
compliance with the conditions stipulated under Article 3 of the Regulation, as follows: 
 
The product named Insulin lispro is protected by the basic patent in force RO 2.192T, having 
the title Insulin Analog Compound and Pharmaceutical Compositions Containing the Same, as 
identified in Claims 1 and 2 and the examples in the description of the basic patent. The condition 
                                                 
2 Regulation (EC) 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the 
supplementary protection certificate for medicinal products (Codified version) (OJ L 152/1) 
3 Under the title Conditions for obtaining a supplementary protection certificate, (hereinafter referred to as 
SPC), Article 3 of the said Regulation provides as follows:  
“A certificate shall be granted if, in the Member State in which the application referred to in Article 7 is 
submitted and at the date of that application:  
(a) the product is protected by a basic patent in force;  
(b) a valid authorization to place the product on the market as a medicinal product has been granted in 
accordance with Directive 65/65/EEC or Directive 81/851/EEC, as appropriate;  
(c) the product has not already been the subject of a certificate;  
(d) the authorization referred to in (b) is the first authorization to place the product on the market as a 
medicinal product.”  
4 State Office for Inventions and Trademarks, Romania, hereinafter OSIM.  
5 Article 19: “Additional provisions relating to the enlargement of the Community  
Without prejudice to the other provisions of this Regulation, the following provisions shall apply: 
[…] (j) any medicinal product protected by a valid basic patent and for which the first authorisation to place it 
on the market as a medicinal product was obtained after 1 January 2000 may be granted a certificate in Romania. In 
cases where the period provided for in Article 7(1) has expired, the possibility of applying for a certificate shall be open 
for a period of six months starting no later than 1 January 2007;” 1134  Challenges of the Knowledge Society. Legal sciences 
provided under letter a) of Article 3 is complied with. No SPC has been granted in Romania in 
respect of said product, the condition provided under letter c) of the same article being also met 
thereby. From the SPC application filed with OSIM, it results that the product Insulin lispro is 
retrieved as an active substance in the medicament named Humalog, authorized for the first time to 
be placed on the market in Romania as a medicinal product through the Registration Certificates no. 
5256/96, 5257/96 and 6764/98 and reauthorized to be placed on the market through the authorization 
no. 3149/2003. Said later authorization obtained by the product as a medicament is an authorization 
granted in accordance with Directive 65/65/EEC of the Council of 26 January 1965 on the 
approximation of provisions laid down by law, regulation or administrative action relating to 
proprietary medicinal products, so that the condition provided under letter b) of Article 3 is met, as 
well. For the cumulative compliance with the four conditions stipulated by Article 3 of the 
Regulation, the authorization no.3149/2003, granted in accordance with Directive 65/65/EEC, needs 
to be the first authorization for placing the product Insulin lispro on the market as a medicinal 
product (Article 3 (d)). It is worth mentioning that the first authorization for placing the product on 
the market, in the Community, was issued on 30.04.1996, as the applicant indicates in the SPC 
application. 
The registration certificates for the medicament Humalog having Insulin Lispro as an active 
substance have been issued by the National Medicines Agency, based on Romanian Government 
Ordinance No. 31/1995 (Official Gazette No.201 of 30.08.1995) and the Order of the Minister of 
Health No.949/1991, which approved the Directives concerning the authorization, registration and 
monitoring of medicaments and other products for human use. These certificates were issued in the 
period of time when the above-mentioned national acts in force had provisions as to the 
harmonization with the Directive 65/65/EEC, with which they were already harmonized to a large 
extent. Based on said certificates, the medicament Humalog could be commercialized in Romania 
before the date of 01.01.2000. Taking into account the meaning of the date of 01.01.2000, i.e. in 
Romania, the first authorizations for placing the medicaments on the market were granted by virtue 
of procedures harmonized with the Directive 65/65 EEC, starting from this date, based on the 
Emergency Ordinance No.152/1999
6, OSIM interpreted the phrase “the first authorization to place a 
product on the market as a medicinal product”, in the Article 19 a (l), as referring to the first 
authorization for placing the product on the market in Romania, not in the Community. It results that 
the right to be granted an SPC in Romania is explicitly limited to those products that cumulatively 
comply with the provisions of Article 3 (b) and (d), and of Article 19 a (l) of the Regulation, in this 
case it being relevant that the product had not been placed on the market in Romania before 
01.01.2000. 
 
Consequently, as the conditions for the grant of the SPC for the product Insulin lispro were 
not cumulatively complied with, the application was refused by the Examination Board, through the 
Decision No.3/29 of 28.12.2008. 
On 17.04.2009, the company Eli Lilly and Company, represented by SCA Turcu & Turcu, 
lodged an appeal against the decision of the Examination Board, with the OSIM Board of Appeal, 
asking for “the annulment of the decision no. 3/29 of 28.12.2008 and, consequently, for the granting 
of a supplementary protection certificate for the medicinal product Humalog – Insulin lispro”. 
The grounds, as claimed in the appeal, related to the fact that Article 19 a (l) of the Regulation 
does not explicitly limit the right to be granted an SPC to the products commercialized on the 
Romanian market, for the first time after the date of 01.01.2000, “but rather relates to the products 
whose first market authorization (as defined in the Regulation) was granted after 01.01 2000. With a 
view to obtaining an SPC in Romania, it is not relevant whether the product was placed on the 
                                                 
6 GEO No. 152/1999 of 14 October 1999 on medicinal products for human use, published in the O.G. No. 508 
of 20 October 1999 and entered into force on 01.01.2000 Bucura Ionescu 1135 
market in Romania before the date of 01.01.2000, as long as those products were not authorized in 
Romania in accordance with a procedure similar to the procedure provided by the Council Directive 
65/65/EEC”. The appellant also showed that a contrary interpretation could lead to an erroneous 
conclusion, namely that, in Romania, an SPC can only be obtained for those products for which the 
first market authorization was obtained in a Community Member State, after the date of 01.01.2000, 
which would limit the purpose of application of the Regulation on the territory of our country. In the 
appellant’s opinion, because Article 19 a (l) relates to Article 3 (b) and (d), the phrase “first 
authorization” used in Article 19 a (l) shall represent the first authorization in Romania. Invoking the 
uniform application of Community legislation, based on the fact that the same product has been 
granted an SPC in the majority of the other EU Member States, the appellant also points out that the 
product Humalog – Insulin Lys Pro obtained the first EMEA market authorization on 30.04.1996, 
which allows the granting of an SPC. The invoked legal grounds are Article 3, Article 17 and Article 
19 a (l) of the Regulation, Article 7(1) of the Law No.93/1998 on the pipeline protection of patents
7, 
Article 51
8 of the Patent Law 64/1991, as republished. 
Subsequently, the appellant also filed written conclusions to prove the unlawful character of 
the appealed against decision to refuse the application for the grant of an SPC. Essentially, the 
appellant considers that the decision appealed against was made as a consequence of the unlawful 
interpretation of the concept of “first authorization to place the product on the market as a medicinal 
product.” With a view to explaining the meaning of the phrase “first authorization to place the 
product on the market”, the appellant applied the reference decision of ECJ – Hässle vs Ratiopharm
9 
to the case: “The first authorization for placing the product on the market in the Community”, 
mentioned under Article 19 (l) in the Regulation No. 1768/92 must be, the same as “the first 
authorization for placing the product on the market “ mentioned under Article 3 of the said 
Regulation, an authorization issued in accordance with the Directive 65/65/EEC.” 
The ruling of the OSIM Board of Appeal as to reject the appeal is pronounced with majority 
of votes through the Decision No. 64/16.07.2009. The Chairman of the Board formulated a separate 
opinion thereto, as to allow the appeal. The grounds of the Board judgment consisted in that the first 
authorizations for placing the product on the market as a medicament were issued as the Registration 
Certificates of 1996 and 1997, granted by the Ministry of Health, based on the Government 
Ordinance No.31/1995 (Official Gazette No. 201/30.08.1995) and the Order of the Minister of 
Health No.949/1991 approving the Directives concerning the authorization, registration and 
monitoring of medicaments and other products for human use. Said Certificates were granted by 
virtue of a procedure following to a great extent the structure and content of the Directive 
65/65/EEC, still not being fully harmonized therewith, but based on a complete authorization file 
which contained a chemical-pharmaceutical and biological documentation, a pharmaco-toxicological 
documentation and a clinical documentation, as well, being elaborated in accordance with the 
European Communities good practice rules on pharmaceuticals. The said acts have permitted the 
circulation and use of the medicament Humalog (Insulin lispro) on the territory of Romania, since 
1996. The legal grounds invoked are Article 18 of the Regulation (codified version) and Article 53 of 
the Patent Law 64/1991, as republished. 
                                                 
7 Law No. 93/1998 on the pipeline protection of patents of 13 May 1998, published in the O.G. No. 186 of 20 
May 1998. By virtue thereof, the pipeline protection starts on the date of filing the patent application with OSIM and 
lasts untilş the date of expiry of the patent. 
8 Article 51 of the Patent Law 64/1991 republished in the Official Gazette of Romania, Part I, No.541 of 
08.08.2007: Any decision made by the Examination Board may be appealed against with OSIM within 3 months from 
communication.” 
9 C-127/00 – The court held with no doubt that there is no reason for different interpretation of the phrase 
„authorization for placing the product on the market”, depending on the provision of the Regulation it is comprised in, 
and that the phrase cannot have different meanings when mentioned under Article 3 or under Article 19. 1136  Challenges of the Knowledge Society. Legal sciences 
In his dissenting opinion, the Chairman of the Board argued that the allowability of the appeal 
was imposed by the reason that said Registration Certificates cannot represent first authorizations to 
place a medicament on the market, as they can be ignored in the meaning of Article 20 of the 
codified version of the Regulation.
10 
The above–mentioned Decision No. 64/16.07.2009 of the OSIM Board of Appeal was 
appealed against by the appellant Eli Lilly and Company, represented by SCA Turcu & Turcu, before 
the Law Court of Bucharest – Civil and Intellectual Property Section, on 28.10.2009, registered 
under the number 42590/3/2009. 
In opposition with the respondent State Office for Inventions and Trademarks (OSIM), and 
pursuant to the provisions of Article 57 (1) of the Patent Law 64/1991 and Article 282 and the 
following of the Civil Procedure Code, the appellant asks for : 
“the delivery of a decision as to allowing the appeal and consequently: 
i)  changing the decision appealed against in whole; 
ii)  accepting the application for the grant of a supplementary protection certificate for the 
medicament Humalog (Human Insulin Lys Pro);[…]” 
 
In the statement of reasons of the attack, the appellant indicates the legal ground for its SPC 
application, i.e. Article 19 a (I) of the Regulation (EEC) 1768/92, and shows that “the condition set 
out under this article is that the medicament had not been given a market authorization before the 
date of 1 January 2000.” And, despite the substantiation in extenso of the fact that the authorization 
referred to under Article 19 (I) is an authorization issued in accordance with the Directive 65/65/EEC 
and, consequently, the Certificates issued in 1996, allowing commercialization in Romania of the 
medicament Humalog, were not issued according to a procedure pursuant to the Directive, these 
essential arguments were not analyzed by OSIM and the Board of Appeal “was content with 
assuming the examiner’s opinion.” Thus, one of the pleas raised by the appellant in support of the 
appeal is the unsubstantiation: the attacked decision has not been substantiated. 
Another plea in support of the appeal is the violation of the principle of equality of arms and 
fair trial
11, as OSIM gave the value of presumption iuris et de iure to a communication from the 
National Medicines Agency setting out that ”the certificates of registration issued before the date of 
01.01.2000, although not fully harmonized with the Directive 65/65/EEC, are based on an extensive 
chemical-pharmaceutical, biological, pharmaco-toxic and clinical documentation” thereby 
preventing the appellant from effectively appealing against its acts. This represented an obvious 
violation of the right to a fair trial. 
Finally, the appellant also invokes the groundlessness of the judgment, as the respondent 
OSIM states that Romanian norms in 1996 were “to a great extent” in accordance with the Directive 
65/65/EEC, even if the procedure was “not fully harmonized”; however, “to a great extent” does not 
mean completely and “not fully harmonized” does not mean identical. 
OSIM filed a statement of defence claiming that the Court should reject the appeal as 
unfounded and, subsidiarily, reject the head of claim concerning the payment of Court costs. In brief, 
the respondent OSIM shows that in Romania the right to obtain an SPC is limited to the products – 
active substances – which cumulatively satisfy the requirements of Article 3 (b) and (d) and Article 
19 (l) of the Regulation, where it is relevant that the product was not placed on the market before the 
date of 01.01.2000, even if it had been already commercialized in the Community. 
The Court ascertains that the decision appealed against was made based on a misinterpretation 
of the applicable legal provisions and allows the appeal. We quote from the statement of reasons of 
the Court: 
                                                 
10 Article 20 is the former Article 19 a (I) of the Regulation No.1768/92 – Additional provisions relating to the 
enlargement of the Community  
11 Principle of equality of arms and the fair trial is applicable in civil matters in the meaning of Art. 6 of ECHR Bucura Ionescu 1137 
  “The Court retained that the problem submitted for trial is to establish whether the 
Registration Certificates no. 5256/1996, 5257/96, 5258/96 and 6764/98, 5488/97, granted by the 
Ministry of Health, represent or not the first authorizations to place the product on the market, 
referred to under Article 3 (d) of the Regulation, as related to Article 3 (b) of the same Regulation 
and the harmonization of the Romanian legislation with the Directive 65/65/EEC. 
These certificates cannot represent a valid authorization for placing the product on the 
market as a medicinal product, in accordance with the Directive 65/65/EEC, and do not comply with 
the requirements of Article 3 (b) and (d) of the Regulation. In support of this interpretation, the Court 
also considered the provisions of Article 8, (1) (b) of the Regulation, stipulating that: “The 
application for a certificate shall contain: […] a copy of the authorization to place the product on 
the market, as referred to in Article 3 (b), in which the product is identified, containing in particular 
the number and date of the authorization and the summary of the product characteristics listed in 
Article 4a of Directive 65/65/EEC”. For the same purpose, the Court retains the case-law of the ECJ 
referring to the rulings in the case C-127/00 Hässle AB vs Ratiopharm. It also judges that a 
medicament that has not been authorized pursuant to the Community law cannot be introduced onto 
the market of a Member State. And there are no provisions in the Directive 65/65/EEC to stipulate 
the possibility of such derogations or to allow one to consider that the mere introduction onto the 
market, even during several years, of a medicament which was not the subject of a market 
authorization issued in accordance with the Community law, could replace such an authorization.”
12 
 
In conclusion, the Court considered that the appellant’s application for the grant of an SPC 
cumulatively satisfies the requirements of Article 3 of the Regulation, as follows: 
 
a)  The product is protected by a basic patent in force, i.e. patent RO 2192T, granted under 
the Law No.93/1998; 
b)  A valid authorization for placing the product on the market as a medicinal product was 
granted in accordance with the Directive 65/65/EEC – Market authorization no. 3149/2003/01 issued 
on 21.02.2003; 
c)  The product has not already been the subject of a certificate; 
d)  The authorization referred to under letter b) is the first authorization for placing the 
product on the market as a medicinal product. 
 
Based on these reasons, ascertaining that the decision appealed against was given with the 
misinterpretation of the incidental legal provisions, through the Civil Matters Decision No. 593 
pronounced in open session on 27.05.2009, the Court allowed the appeal lodged by the appellant Eli 
Lilly and Company against the Decision No. 64/16.05.2009 made by the respondent OSIM and 
ordered the same to grant the SPC for the product Humalog (Human Insulin Lys Pro). The decision 
remained final and irrevocable by lack of appeal. 
 
Consequently, OSIM granted the Supplementary Protection Certificate for the product 
Humalog (Human Insulin Lys-Pro) valid from the date of 07.02.2010 until 30.04.2011.  
 
2.  Case Anastrozole (the medicament named “Arimidex”). File No. 42583/3/2009, Law 
Court of Bucharest, Fifth Civil Section 
The supplementary protection certificate application no. c2007-080 of the applicant 
AstraZeneka UK Limited for the product of the ICD Anastrozole (active substance having the 
chemical name 2,2’-[5-(1H-1,2,4-triazole-1-methyl)-1,3-phenylene]di(2-methylproiononitrile), 
                                                 
12 Decision No. 593 of the Law Court of Bucharest, Fifth Civil Section, pronounced in open session on 
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possibly as a pharmaceutically acceptable addition salt, was filed with OSIM on 29.06.2007, within 
the 6-month legal time limit of Romania’s accession to the European Union, under the transitional 
provisions stipulated in Article 19a (I) of the Regulation. 
 
With a view to granting the SPC applied for, the Examination Board of OSIM analyzed the 
compliance with the conditions stipulated under Article 3 of the Regulation, as follows: 
The product named Anastrozole, optionally as a pharmaceutically acceptable addition salt, is 
protected by the basic patent in force, RO 2.189T having the title “Aralkyl-Substituted Heterocyclic 
Compounds and Pharmaceutical or Veterinary Composition Containing the Same”, as identified in 
Claims 1 and 7 (first compound) and first example in the description of the basic patent. The 
condition provided under letter a) of Article 3 is complied with. No SPC has been granted in 
Romania in respect of said product, the condition provided under letter c) of the same article being 
also met thereby. From the SPC application filed with OSIM it results that the product Anastrozole is 
retrieved as an active substance in the medicament Arimidex, authorized for the first time to be 
placed on the market in Romania as a medicinal product through the authorization (Registration 
Certificate) no. 92/1999/01 of 27.05.1999 and reauthorized to be placed on the market through the 
market authorization no. 6459/2006/01 of 31.05.2006. The first authorization for placing the product 
on the market in EEA is the authorization no. PL12619/0106 granted on 11.08.1995, in the United 
Kingdom. For the cumulative compliance with the four conditions stipulated by Article 3 of the 
Regulation, the market authorization no. 6459/2006/01 of 31.05.2006, granted in accordance with the 
Directive 65/65/EEC, needs to be the first authorization to place the product Anastrozole on the 
market, as a medicinal product (Article 3 d). 
OSIM ascertained that, based on the authorization no. 92/1999/01 of 27.05.1999, the 
medicament Arimidex could be commercialized in Romania before the date of 01.01.2000. 
In a similar way with the Humalog cas, as the conditions for the grant of the SPC for the 
product Anastrozole have not been cumulatively complied with, the application was refused by the 
Examination Board, through the Decision No. 3/20 of 30.10.2008
13.  
On 26.02.2009, the applicant AstraZeneka UK Limited, represented by SC Rominvent SA, 
lodged an appeal against the decision of the Examination Board, with the OSIM Board of Appeal, 
asking for the annulment of the decision of the Examination Board and admission of the SPC 
application c2007-080. The legal ground invoked: Article 17 of the Regulation, Article 51 (1) of the 
Patent Law 64/1991, as republished. 
As an argument in favour of granting the SPC, the appellant invokes Article 2 of the 
Regulation, mentioning that: “Article 2 in the Regulation No.1768/1992 provides that the medicinal 
product in respect of which the SPC is applied for should be the subject of a valid authorization for 
placing the product on the market, issued in accordance with the Directive 65/65/EEC (applicable to 
medicinal products for human use) abrogated by Directive 2001/83/EC, or the Directive 81/851/EEC 
(in case of medicinal products for veterinary use) abrogated by Directive 2001/82/EC on the 
Community code relating to veterinary medicinal products”.
14  
                                                 
13 From the whole number of SPC applications filed with OSIM under Article 19 (I) of the Regulation, for 
products contained in medicaments commercialized on the territory of Romania before the date of 01.01.2000, based on 
certificates or authorizations which were not fully harmonized with the Directive 65/65/EEC, the first decision to refuse 
the application was made in respect of Anastrozole. The chronology of the decisions is only relevant in the light of the 
evolution of the grounds invoked by the representatives of patent owners upon attacking OSIM decisions.  
14 Text of Article 2 of the Regulation No. 1768/1992: Scope  
“Any product protected by a patent in the territory of a Member State and subject, prior to being placed on the 
market as a medicinal product, to an administrative authorization procedure as laid down in Council 
Directive 65/65/EEC… may, under the terms and conditions provided for in this Regulation, be the subject of a 
certificate.” Bucura Ionescu 1139 
It also relies on the above-mentioned case Hassle vs Ratiopharm in order to substantiate the 
identity between the authorization referred to under Article 3 and the authorization under Article 19 
of the Regulation, which must be in accordance with the Directive 65/65/EEC. 
The ruling of the OSIM Board of Appeal as to reject the appeal is pronounced with majority 
of votes through the Decision No. 67/25.05.2009. The Chairman of the Board expressed a separate 
opinion thereto, as to allow the appeal. The ground of the Board judgment is similar with the 
Humalog case. The legal grounds invoked in support thereof are Article 20 of the Regulation (EC) 
No.469/2009 concerning the SPC for medicaments and Article 53 of the Patent Law 64/1991, as 
republished.  
In his dissenting opinion, the Chairman of the Board argued that the allowability of the appeal 
was imposed by the reason that said Registration Certificates cannot represent first authorizations to 
place a medicament on the market, as they can be ignored in the meaning of Article 20 of SPC 
Regulation No.469/2009 (EC). He also referred to the case no. HC 08 C 02210 Synthon B.V. vs 
Merz Pharma of 02.04.2009, where the judge Justice Floyd presented a judgment of 
Bundespatentgericht of 11.12.2007 (pages 7-8) and stated that old authorizations, granted in 
accordance with the unharmonized legislation, are not taken into account by the Federal Patent Court 
of Germany. 
The above-mentioned Decision No. 67/25.05.2009 of the OSIM Board of Appeal was 
appealed against by the appellant AstraZeneka UK Limited, represented by SCA David and Baias, 
before the Law Court of Bucharest – Civil and Intellectual Property Section, on 28.10.2009, under 
the number 42583/3/2009. In opposition with the respondent OSIM and pursuant to the provisions of 
Article 57 (1) of the Patent Law No. 64/1991 and Article 282 and the following of the Civil 
Procedure Code, the appellant claims that the Court should: 
i)  invalidate the Decision appealed against in whole; 
ii)  order OSIM to issue an SPC for the product Arimidex, with the active substance 
Anastrozole; […]. 
In the statement of reasons of the attack, the appellant indicates first that, although the 
Decision of the OSIM Board of Appeal is related to the Regulation (EC) No. 469/2009, which is the 
codified version of the SPC Regulation No. 1768/1992, reference will be made to the consolidated 
text of the Regulation, prior to the codification of 2009. The appeal is based on the unlawfulness and 
groundlessness of the Decision made by the Board of Appeal, the appellant putting forward its 
arguments to prove that: 
 
1.  The first authorization for placing the product on the market, within the meaning of Article 
3 (d) of the Regulation must be a market authorization harmonized with the Directive 65/65/EEC.  
In order to support the uniform application, at the Community level, of the Regulation, and 
thus, of the national procedures for medicaments authorization, which must be in compliance with 
the Directive 65/65/EC, the appellant relies on the cases Hassle AB vs Ratiopharm GmbH and 
Pharmacia Italia SpA. Because almost 30 years elapsed from the adoption of the Directive, in 1965, 
to the issuance of the Regulation, in 1992, it is “impossible to retain that Article 3 (d) would relate to 
a market authorization unharmonized with the Directive.”  
2.  The market authorization-1999 (in fact the Registration Certificate of 1999) was not issued 
by virtue of a procedure harmonized with the Directive 65/65/EEC. 
 
Starting from the assertion of the respondent OSIM itself, that the Certificate of 1999 was not 
harmonized with the Directive, the appellant points out the meaning of the date of 01.01.2000, and 
states: 
 
“Thus, from the viewpoint of the Regulation purpose, the market authorizations issued after 
the date of 01.01.2000, under the GEO No. 152/1999, comply with the Directive 65/65/EEC and can 1140  Challenges of the Knowledge Society. Legal sciences 
give the right to the grant of an SPC, while the market authorizations issued prior to this date, under 
the GO 31/1995 do not comply with the Directive 65/65/EEC and, by consequence, cannot be relied 
upon for the grant of an SPC. In other words, the date of 01.01.2000 is mentioned by this text only 
because the grant of any authorization in accordance with the Directive would not have been 
possible prior to this date. Consequently, the conclusion of the OSIM “analysis” alleging that the 
presence of the product on the Romanian market before the date of 01.01.2000 would represent a 
reason of non-compliance with the Regulation requirements for the grant of an SPC is obviously 
erroneous and lacks any legal support.”
15 
 
The statement of reasons of the Court findings is identical with the statement in the Humalog-
Insulin lispro. It is found that the first authorization to place the product on the market is not the 
Registration Certificate No. 92/1991/01, but the market authorization no. 6459/2006/01 issued on 
31.05.2006 under the GEO No. 152/1999 harmonizing the national legislation with the Directive 
65/65/EEC, coming to the conclusion that the decision appealed against was given with the 
misinterpretation of the legal provisions. OSIM was ordered to grant the SPC for the product 
Arimidex. 
The Decision No. 523/13.05.2010 of the Law Court of Bucharest was further appealed against 
by OSIM. 
This further appeal was based on the consideration that, in ruling the appeal brought against 
the OSIM Board of Appeal, the Court misinterpreted the provisions of Article 3 and Article 19 a (I) 
of the Regulation. As, under Article 267 of the Treaty on the Functioning of the European Union 
(former Article 234 EC), the mission of ensuring application, interpretation and enforcement of 
Community law throughout the territory of the EU is incumbent on the European Court of Justice, 
OSIM found necessary that the following question should be referred to the ECJ for preliminary 
ruling
16: 
 
“Does an authorization granted in Romania, which is in accordance with the Council 
Directive 65/65/EEC, represent for a product “the first authorization for placing the product on 
the Romanian market as a medicinal product”, provided that this authorization was obtained 
following to a request for reauthorization based on a prior authorization issued under certain 
normative acts harmonized “to a great extent” with the Directive 65/65/EEC?”  
 
Through a statement of defence, AstraZeneka UK Limited, represented by SCA Baias and 
Baias, asks the Court of Appeal to reject the appeal entered by the respondent OSIM, as unfounded, 
invoking, on the one hand, that there is no need of a preliminary ruling of the ECJ concerning the 
interpretation of Article 3 of the Regulation, and, on the other hand, that the Law Court of Bucharest 
considered correctly that the market authorization of 2006 was the first authorization for placing the 
product Arimidex on the market, within the meaning of Article 3 (d) read in conjunction with Article 
3 (b) of the Regulation. The preliminary ruling of ECJ is considered unnecessary for the following 
reason: “the concept of “first authorization for placing a product on the market” was settled by the 
ECJ in the case C-127/00 Hassle vs Ratiopharm GmbH, the court being not obliged de plano to refer 
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TFEU, as well as in accordance with the Information Note on references from national courts for a preliminary ruling, 
published in the JO No.297 of 5 December 2009 and Article 23 in the Statutes of the European Court of Justice, where 
an instance has doubts on the interpretation of an act issued by a European institution, it may refer the case to the ECJ 
for preliminary ruling.  Bucura Ionescu 1141 
the case to the ECJ considering that a question within the meaning of Article 267 TFEU was 
raised.
17”  
 
The company Teva Pharmaceuticals SRL, represented by SCA Nestor Nestor Diculescu 
Kingston Petersen, entered, based on Article 49 (1) and (3) read in conjunction with Article 51, 54, 
55 and 56 of CCP, an application for intervention in the interest of OSIM and in opposition with 
AstraZeneka UK Limited, claiming, among other things, that the Court should allow the appeal 
entered by OSIM and change the decision made by the Law Court of Bucharest
18. Teva 
Pharmaceuticals SRL justified its interest in the case Anastrozole by its being the owner of the 
authorization for placing on the Romanian market the generic medicament Anastrozole TEVA, 
having the anastrozole as an active principle. Because the patent RO 2189T has expired since 
14.06.2008, the company which manufactures generic medicaments is interested in the 
commercialization, on the Romanian market, of the generic medicament containing the active 
substance/principle Anastrozole, for which it already obtained the market authorization. The 
extension of the SPC duration may thereby affect the rights of the company to commercialize its 
products, rights obtained upon issuance of the market authorization. The arguments brought by the 
intervener in order to support the lack of legal grounds of the decision made by the Law Court of 
Bucharest concerning Article 3 and Article 19 a (I) of the Regulation are the following: 
 
A. Arguments based on the interpretation of legal texts 
 
Article 19 a (l) is an amendment brought to Article 19 a as a consequence of the Act of 
Accession of Bulgaria and Romania to the EU
19. This article originates in Article 32 of the Law No 
581/2004 on the supplementary protection certificate for medicaments and plant-protection 
products”
20 which has the following content: 
 
“a certificate may be granted for any product which, on the date of entering into force of this 
law, is protected by a basic patent in force or by a pipeline protection certificate in force and for 
which  a first authorization to be placed on the Romanian market as a medicament or plant 
protection product was obtained starting from 1 January 2000, provided that the application for the 
grant of the certificate is filed within a time limit of 6 months of the date of Romania’s accession to 
the European Union.”  
 
Hence, as regards Romania, an SPC cannot be granted if the first authorization for placing a 
medicament on the market was issued before the date of 1 January 2000. 
 
B.  Arguments based on the interpretation of similar legal texts by other Member States 
                                                 
17 Paul Craig, Greinee de Burca – Dreptul Uniunii Europene, Fourth Edition, Ed. Hamangiu, Bucharest 2009, 
p. 585 
18 From the Application for accessory intervention entered by NNDKP, only the aspects relating to the appeal 
lodged by OSIM shall be hereinafter referred to. 
19 The Act of Accession of Romania and Bulgaria to the EU was published in the Official Journal of the 
European Union No. L 157/11 of 21.06.2005. In Annex III to the Protocol setting the conditions and arrangements for 
accession, the chapter concerning the company law contains the Industrial Property Rights section with the sub-section 
Supplementary Protection Certificates. 
20 Law No.581/2004 on the supplementary protection certificate for medicaments and plant protection products 
was published in the Official Gazette of Romania No. 1233 of 21 December 2004. The law never produced effects and 
was expressly abrogated by the Law No. 107/2007, because, on the date of Romania’s accession to the European 
Union, the Community Regulations became directly applicable and prevailing over the conflicting provisions of 
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It is the case of Hungary and Poland. For the transitional (pipeline) protection in the two said 
Member States, there are applicable the provisions of Article 19 a (f) and (h), respectively. In this 
two Member States, the same as in Romania, the transitional provisions of Article 19 a do not 
expressly refer to a first market authorization obtained in the respective Member State, as is the case 
in Cyprus, Estonia, Latvia, Lithuania, Malta, Slovenia and Slovakia. In its position of additional 
negotiation in the view of its accession to the EU, the government of Hungary upheld the 
applicability of the SPC regime only for those medicaments whose first authorization to be 
placed on the Community or Hungarian market (or the market of other countries in course of 
accession) was obtained after 1 January 2000, position which was accepted by the EU. 
 
The interpretation presented above is also applicable to Poland, where an SPC cannot be 
granted for a product whose market authorization was obtained before the date of 1 January 2000, in 
Poland or in any Member State, as mentioned in the specialized literature
21. 
 
C.  Arguments based on the interpretation of the European Court of Justice 
 
In the case C-66/09: Kirin Amgen. Inc. vs Lietuvos Respublikos valstybinis patent biuras, the 
ECJ concludes: “the objective pursued by Regulation No 1768/92 of according uniform protection 
for a medicinal product throughout the European Union does not preclude transitional provisions, 
resulting from the accession negotiations, which may mean that it is not possible to apply for an SPC 
for certain medicinal products in certain Member States. This outcome, which may impede, even if 
only temporarily, that objective and the functioning of the internal market, is justified by the 
legitimate objectives concerning health policies, including, as the case may be, the financial stability 
of the health systems of the Member States”. 
 
D. Arguments based on an interpretation per a contrario  
 
Having in view that from the transitional provisions concerning states as Malta or Slovenia, 
from the wording of sub-paragraphs (g) and (i), it explicitly results that the first authorization for 
placing a product on the market relates to Malta or Slovenia, respectively, while the wording of sub-
paragraph (I) concerning Romania is comparable with the situation of Hungary and Poland, it 
obviously outcomes that the interpretation of the provisions of the Regulation cannot lead with 
certainty to the conclusion that, in Romania, an SPC may be granted for a product for which an 
authorization for placing it on the market was obtained before the date of 1 January 2000 in any 
Member State, as interpreted by the Romanian Law Court of Bucharest. 
The intervener further invokes the provisions of Article 2 of the Regulation. 
The two requirements of this article provide that the product should be protected by a basic 
patent and should be subjected to authorization, pursuant to the Directive, prior to its being placed on 
the market. The provisions of Article 2 differ from those of Article 3 (a) and (b) in that Article 2 
excludes from its scope the products placed on the market in the absence of an authorization pursuant 
to the Directive 65/65. Moreover, if the grant of an SPC based on other authorizations than those 
pursuant to the Directive were possible, the period of exclusivity would exceed, in certain cases, the 
total limit of 15 years from the date of the first authorization in Community, mentioned within the 
eighth recital of the preamble of the Regulation. 
Finally, the arguments relating to the logic of the Regulation could be summarized by the 
following deduction: if the authorizations legally obtained before the date of 1 January 2000 could 
not be deemed to be the first authorizations for placing a medicament on the market, for lack of 
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compliance with the Directive, the reference date mentioned under Article 19 a (l) (i.e. 1 January 
2000) would be completely useless, as all the products having market authorization received after 
this date would be automatically eligible for the grant of an SPC (no market authorization in 
compliance with the said Directive was obtained before this date). 
 
The intervener claimed that six questions should be referred to the European Court of Justice 
for preliminary ruling. Of these questions, we will mention the following: 
 
1.  In the meaning of Article 20 (j) (former Article 19 a (l)), may an SPC be granted in 
Romania for a product whose first market authorization, pursuant to the Directive 65/65/EEC, was 
obtained before the date of 1 January 2000 in any Member State? 
 
2.  Should the answer in the first question be in the affirmative, is a product firstly authorized 
to be placed on the market in Romania, before the date of 1 January 2000, without the administrative 
procedure provided for by the Directive 65/65, eligible to be granted an SPC in accordance with the 
Regulation?  
 
 
3.  Within the meaning of Article 3 (d) of the Regulation, is an authorization issued in 
accordance with the legislation in force in Romania before the year 2000, and which was not in 
compliance with the Directive 65/65 but allowed the product to be legally placed on the market, 
deemed to be the first authorization for placing a product on the market as a medicinal product? 
The application to intervene is dismissed by the Court of Appeal of Bucharest – Ninth Civil 
Section for cases concerning intellectual property, based on the grounds invoked in the Statement of 
defence filed by AstraZeneka UK Limited, represented by SCA David and Baias. There was invoked 
the objection of inadmissibility of the legal strategy proposed by the intervener, namely the fact that 
the product Anastrozole is not within the scope of the Regulation, i.e. Article 2. Firstly, a new legal 
argument was invoked, i.e. Article 2, despite the fact that OSIM did not invoke or contest this article 
in its decisions; secondly, by invoking Article 2, the principle of availability was violated. Thus, 
OSIM entered its further appeal relying on the ground referred to under Article 304 (9) of the CPC, 
i.e. “wrongful application of law”, in relation with Article 3 and Article 19 a (I) of the Regulation, 
which are the only legal norms under assessment by the Examination Board, Board of Appeal and 
Law Court of Bucharest. Whereas Article 2 was not the subject of a dispute between the parties, the 
arguments brought in support of the appeal entered by OSIM cannot be allowed. Thirdly, the fact of 
invoking Article 2 violates the principle of double jurisdiction, since the intervener Teva may not 
invoke criticism on applicability and interpretation of legal texts which were not discussed before the 
Law Court of Bucharest, but are brought, for the first time, before the Court of Appeal. 
Although, in the Written Conclusions sent to the Court of Appeal on 08.02.2011, OSIM 
reiterates the need to refer the questions on the interpretation of Article 19 a of the Regulation for 
preliminary ruling by the ECJ, provided that, in SPC matters, after Romania’s accession to the EU 
there is no corresponding case-law, the Court of Appeal is a court whose decisions cannot be subject 
of internal attack, and “ the preliminary ruling system is a fundamental mechanism of European 
Union law aimed at enabling national courts to ensure uniform interpretation and application of that 
law in all the Member States”
22, this request is rejected by the Court.  
The Court of Appeal dismisses the appeal entered by OSIM before the Court of Appeal of 
Bucharest against the Decision No. 523/13.05.2010 of the Law Court of Bucharest as unfounded and, 
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at the same time, it rejects as groundless the application to intervene filed by Teva Pharmaceuticals 
SRL in the interest of OSIM. The Decision of the Law Court of Bucharest is thereby irrevocable. 
 
As a consequence, OSIM granted the Supplementary Protection Certificate for the product 
Anastrozole, possibly as a pharmaceutically-acceptable addition salt, valid from 15.06.2008 until 
11.08.2010.  
 
3.  Case Olanzapine (the medicament named Zyprexa). File No. 42589/3/2009, Law Court 
of Bucharest, Fifth Civil Section 
The supplementary protection certificate application no. c2007-058 of the applicant Eli Lilly 
and Company, for the product having the ICD Olanzapine (the active substance with the chemical 
name 2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]benzodiazepine), was filed with 
OSIM on 14.06.2007, within the 6-month legal time limit of Romania’s accession to the European 
Union, under the transitional provisions stipulated in Article 19a (l) of the Regulation. 
With a view to granting the SPC applied for, the Examination Board of OSIM analyzed the 
compliance with the conditions stipulated under Article 3 of the Regulation, as follows: 
The product named Olanzapine is protected by the basic patent in force, RO 2.168T having 
the title Pharmaceutical Compounds and Pharmaceutical Compositions as identified by Claims 1 
and 7 of the basic patent. The condition provided under letter a) of Article 3 is complied with. No 
SPC has been granted in Romania in respect of said product, the condition provided under letter c) of 
the same article being also met thereby. From the SPC application filed with OSIM it results that the 
product Olanzapine is retrieved as an active substance in the medicament named Zyprexa, authorized 
for the first time to be placed on the market in Romania as a medicinal product through the 
Registration Certificates no. 5920/1997, 5970/1997 and 5931/1997 by the Ministry of Health, based 
on the Government Ordinance No 31/1995 and the Order of the Minister of Health No. 949/1991 
mentioned above. The authorization for placing the product on the market on which the SPC 
application is based is the market authorization no. 1806/2001/01 of 23.03.2001. The first 
authorization for placing the product on the market in EEA is in fact a series of authorizations issued 
by EMEA on 27.09.1996. For the cumulative compliance with the four conditions stipulated by 
Article 3 of the Regulation, the market authorization of 2001, granted in accordance with the 
Directive 65/65/EEC, needs to be the first authorization to place the product Olanzapine on the 
market, as a medicinal product (Article 3 d). 
The case is identically similar with the first two cases presented above, i.e. Insulin lispro and 
Anastrozole, hence we will not analyze it in detail. The SPC application was refused by the 
Examination Board through the Decision No.3/21 of 30.10.2008. 
On 25.02.2009, the company Eli Lilly and Company, represented by SCA Turcu & Turcu, 
lodged an appeal against the decision of the Examination Board, with the OSIM Board of Appeal, 
asking for “the appeal to be allowed, the Decision no. 3/21 of 30.10.2008 to be annulled and a 
supplementary protection certificate to be granted for the medicinal product Zyprexa (Olanzepine)”. 
 
The statement of reasons of the appeal is similar to the Insulin lispro case-file and, following 
to the analysis of the reasons and documents enclosed with the case-file, the OSIM Board of Appeal 
decided to reject the appeal by virtue of the same de facto and de jure considerations referred to in 
the Insulin lispro case-file. 
The Decision No. 62/16.07.2009 of the OSIM Board of Appeal as to reject the appeal, was 
appealed against by the appellant Eli Lilly and Company, represented by SCA Turcu & Turcu, in 
opposition with the respondent State Office for Inventions and Trademarks (OSIM). It was ruled 
through the Civil Decision No. 875A pronounced in open session on 07.07.2010 by the Law Court of 
Bucharest, Fifth Civil Section. The grounds and arguments as to accept the application for the grant 
of an SPC for Olazepine are the same as those referred to in the previously presented case Humalog Bucura Ionescu 1145 
(Insulin lis pro). Also, the statement of reasons of the Civil Decision No. 875A is identical with the 
Civil Decision No. 593 pronounced in open session on 27.05.2009 in respect of the Humalog case. 
But this time, the Civil Decision No. 875A is further appealed against by OSIM which asks 
the Court of Appeal of Bucharest for preliminary ruling by the European Court of Justice. The 
procedural steps and arguments brought by the parties are further on carried out in a way similar with 
the Anastrozole file. Teva Pharmaceuticals Europe BV also applies for accessory intervention. In the 
session of 23.12.2010, the Court adjourns the case with the following ruling: it unanimously 
dismisses the Teva application for accessory intervention as inadmissible and ascertains, with 
majority, the admissibility of principle of the intervention application, with the dissenting opinion of 
judge Stanciu as to the inadmissibility of the intervention application.
23 Through the Civil Decision 
No. 84/01.03.2011 it dismisses the appeal as unfounded and dismisses the application to intervene. 
The Court Decision is irrevocable. 
Consequently, OSIM grants the Supplementary Protection certificate for the product 
Olanzapine, valid from 25.04.2011 until 27.09.2011. 
 
4.   Case Candesartan Cilexetil (Atacand). File No. 35794/3/2011, Law Court of 
Bucharest 
 
The supplementary protection certificate application no. c2007-079 was filed with OSIM by 
Takeda Pharmaceutical Company Limited (hereinafter Takeda), based on the pipeline protection 
patent RO 2005T, granted on 31.08.1999, protecting the active substance Candesartan cilexetil and 
having the expiry date on 19.04.2011. The first authorization for placing the product on the market in 
the European Economic Area (EEA) under the number PL 15661/0001/0002/0003/0004, obtained by 
Takeda in UK, on 29.04.1997, for the medicament Atacand containing the patented product, is 
mentioned in the application form. 
On 23.09.1998, the Ministry of National Health authorized the medicament Atacand, having 
Candesartan cilexetil as an active substance, to be placed on the Romanian market by issuing the 
Registration Certificates no. 7480/23.09.1998, 7481/23.09.1998 and 7479/23.09.1998. On 
02.04.2003, Takeda applied with the National Medicines Agency for the reauthorization of the 
medicament Atacand and obtained the market authorizations no. 6959/2006/01 and 6960/2006/01 of 
17.12.2006, granted through a procedure in accordance with the provisions of the Directive 
65/65/EEC. The SPC application mentioned the market authorization of 2006 as the first 
authorization for placing the medicament on the market, in Romania, and asked for the extension of 
protection for the product 1-(cyclohexyloxycarbonyloxy)ethyl- 2-ethoxy-1-[[2’-(1H-tetrazol-5-
yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate - Candesartan cilexetil in the basic patent. 
Following to the analysis of the application documents, the SPC application was refused 
through the Decision No. 3/16 of 30.10.2008 of the Examination Board of OSIM, on the ground of 
not cumulatively complying with the conditions for the grant of an SPC, stipulated under Article 3 
(b) and (d), and Article 19a (I) of the Regulation. In fact, the Board considered that the market 
authorization of 2006 was not the first market authorization of the product, as said product had been 
commercialized in Romania since 23.09.1998, based on the Registration Certificates. Moreover, said 
market authorization represents a reauthorization. The Decision No. 3/16 of 30.10.2008 was attacked 
by appeal lodged with OSIM. 
Through the Decision No. 66/25.09.2009, the OSIM Board of Appeal rejected the appeal 
entered by Takeda, maintaining the decision to refuse the application. 
The above-mentioned decision 66/25.09.2009 of the Board of Appeal was appealed against 
by the applicant Takeda, before the Law Court of Bucharest, the subject of the case-file no. 
42584/3/2009. The reasons invoked were the same as in the previous cases and we will not insist 
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thereupon, as the cases are identical. The appeal brought by Takeda was allowed by the Law Court of 
Bucharest in an open session, on 11.05.2010, the Court changed the Decision 66/25.09.2009 of the 
Board of Appeal in whole and ordered OSIM to grant an SPC for the product Candesartan cilexetil. 
The Civil Decision No.626A/11.05.2010 remained final and irrevocable by lack of appeal and OSIM 
granted the SPC applied for, valid from 20.04.2011 to 29.04.2012. 
 
The case differs from the other cases presented before in that a Romanian medicaments 
company, Teva Pharmaceuticals SRL, filed with OSIM, on 29.03.2011, a request for revocation of 
SPC Atacand, invoking the violation of the provisions of Article 2 and Article 19a (I) of the 
Regulation. 
 
As regards Article2, Teva takes the view that: ”a product authorized to be placed on the 
market as a medicinal product for the first time in Romania, without being subjected to the 
administrative procedure provided for by the Directive 65/65/EEC (such as Candesartan cilexetil), 
should not be eligible for protection by SPC, in accordance with the provisions of the SPC 
Regulations and, consequently, does not enter within the scope of Article 2”
24.  As regards the 
violation of the provisions of Article 19a (l) of the Regulation, within the same Request for 
revocation, Teva mentions that: “the wording of Article 19a (l) is the direct result of negotiations 
carried out by Romania in the process of its accession to the European Union” and from the 
historical interpretation of legal texts, it results that the said article “sets out an exception from the 
general rule, currently applicable at the Community level, and this is why the said article should 
have, in its turn, a restrictive interpretation which must be supported by the case-law and the 
doctrine based on the interpretation of other identically similar legal texts adopted by other Member 
States of the European Union, as well as the interpretation of the European Court of Justice”. The 
request for revocation does not expressly refer to the unlawfulness of application of Article 3 of the 
Regulation.  
On 19.05.2011, Teva also brought before the Court an Action for Invalidation of SPC, in 
opposition with Takeda and with OSIM as issuing authority, based on Article 54 (1) of the Patent 
Law, as republished, read in conjunction with the provisions of Article 2, Article 3 (b) and (d), 
Article 15, Article 17, Article 18 and Article 19a (I) of the Regulation, read in conjunction with the 
provisions of Article 109 (1) and Article 112 of the Civil Procedure Code. The action is the subject of 
the case-file no.35794/3/2011 pending in the Law Court of Bucharest. In supporting the plea of 
violation of said Community provisions, Teva relied on the same arguments, as well as on an 
identical reasoning as in the Request for Revocation. Takeda, represented by D&B David and Baias 
SCA, filed with OSIM, based on Article 58 (5) and Article 59 (6) of the Implementing Regulations to 
the Patent Law No.64/1991, as republished, a request to suspend the proceedings concerning the 
Request for Revocation of SPC until a final and irrevocable decision is made in the case of the 
Action in Annulment pending before the Law Court of Bucharest.  
We find that the request to suspend the proceedings, filed by Takeda with OSIM, is well 
founded, taking into account that the lawfulness of the SPC Atacand in relation with Article 2, 
Article 19a (I) and Article 3 are concomitantly assessed by OSIM, by means of the request to 
suspend the proceedings, and by the Law Court of Bucharest, by means of the Action in Annulment, 
in the case-file no. 35794/3/2011. The judgment to be given thereupon by the Law Court of 
Bucharest shall be enforceable judgment for OSIM, given its opposable and mandatory 
characteristics, hence, it shall play a decisive role as regards the ruling to be made by OSIM. In order 
to prevent contradictory rulings to be made with regard to the same case, with undesirable effects 
upon the stability of the legal relationship between the parties, it would be desirable that OSIM 
orders the proceedings concerning the Request for Revocation of SPC c2007-07912 to be suspended. 
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At the same time, we assume the argument of Takeda according to which the grant of the SPC 
Atacand by OSIM does not represent the finality of a procedure carried out within OSIM, but “the 
exclusive result of enforcing the Decision No 626A made by the Law Court of Bucharest on 
11.05.2010, judgment by which the lawfulness and groundedness of the application for the grant of 
the SPC Atacand has been finally and irrevocably decided by the law courts […]. In this context, as 
OSIM is the administrative authority which observed the imperative provisions of a judicial decision, 
[…] only the law courts could decide upon the lawfulness of the grant of the SPC Atacand, and not 
OSIM, to which the decisions of the law courts are mandatory and enforceable.” (page 7 of the 
Request to suspend the procedure filed with OSIM on 16.12.2011) 
 
5.   Case Donepezil and the Pharmaceutically Acceptable Salts Thereof (Aricept). File 
No.19925/3/2010 – Court of Appeal of Bucharest 
The supplementary protection certificate application no. c2007-073 was filed with OSIM, on 
27.06.2007, by the applicant Eisai Co. Ltd. of Japan (hereinafter Eisai), through the professional 
representative Cabinet Margareta Oproiu, based on the pipeline protection patent RO 2004T, 
protecting the active substance Donepezil hydrochloride. The first authorization for placing the 
product on the market in the European Economic Area (EEA), under the numbers 10555/0006 and 
10555/0007, obtained by Eisai in UK, on 14.02.1997 for the medicament Aricept, containing the 
product Donepezil protected by the above-mentioned patent, is mentioned in the application form.  
 
On 14.01.1998, the Ministry of National Health authorized the medicament Aricept, having 
Donepezil as an active substance, to be placed on the Romanian market by issuing the Registration 
Certificates no. 6662/1998 and 6663/1998. On 29.04.2005, Eisai applied with the National Medicines 
Agency for the reauthorization of the medicament Aricept and obtained the market authorizations no. 
5307/2005/01 and 5308/2005/01, granted through an administrative procedure in accordance with the 
provisions of the Directive 65/65/EEC. 
The SPC application mentioned the market authorization of 2005 as the first authorization for 
placing the medicament on the market, in Romania, and asked for the extension of protection for the 
product 2-[(1-Benzyl-4-piperidyl(methyl)]-5,6-dimethoxy-2,3-dihydroinden-1-one and the 
pharmaceutically acceptable salts thereof, according to Claims 1 – 3 and 5 and Example 4 of the 
basic patent. 
Following to the analysis of the application documents, the SPC application was refused 
through the Decision No. 3/15 of 30.10.2008 of the Examination Board of OSIM, on the ground of 
not cumulatively complying with the conditions for the grant of an SPC, stipulated under Article 3 
(b) and (d) and Article 19a (I) of the Regulation.  
Through the Decision No. 12/25.02.2010, the OSIM Board of Appeal rejected the appeal 
entered by Eisai, maintaining the decision to refuse the application. 
The said Decision 12/25.02.2010 of the Board of Appeal was appealed against by the 
applicant Eisai before the Law Court of Bucharest, said appeal being the subject of the case-file no. 
19925/3/2010. The reasons invoked were the same as in the previous cases, and we will not insist 
thereupon, as the cases are identical. The matter pending before the Court was to establish whether 
the Registration Certificates of 1998 are or are not the first authorizations for placing the medicament 
Aricept on the Romanian market, referred to under Article 3 (d), as related to Article 3 (b) of the 
Regulation and the harmonization of Romanian legislation with the Directive 65/65/EEC. 
The Law Court of Bucharest allowed, in the open session of 19.10.2010, the appeal brought 
by Eisai and decided to change the attacked decision in whole as to allow the request in the 
application c2007-073 for the grant of an SPC for Donepezil and the pharmaceutically acceptable 
salts thereof, particularly the hydrochloride. 
The Civil Decision No. 1087A/19.10.2010, given by the Law Court of Bucharest in respect of 
the case-file no. 19925/3/2010, was further appealed against by OSIM before the Court of Appeal of 1148  Challenges of the Knowledge Society. Legal sciences 
Bucharest. The appeal relies on the ground that the attacked Decision was given with wrong 
application and interpretation of the law, as provided under Article 304 (9) of the Code of Civil 
Procedure. Thus, in this Decision, it was found that the Registration Certificates of 1998 were not the 
first authorizations to place the medicament Aricept on the Romanian market, because it was found 
that the first market authorization obtained by virtue of a procedure harmonized with the Directive 
65/65/EEC was the market authorization no. 5307/2005, finally coming to the obviously unlawful 
and groundless conclusion that this authorization is, at the same time, the first authorization for 
placing the product on the market, in Romania. However, the condition set forth by Article 3 (d) of 
the Regulation provides that the authorization obtained in accordance with the Directive should be 
the first authorization for placing the product on the market as a medicinal product, and said 
provisions cannot be interpreted within the meaning that the first authorization obtained in 
accordance with the Directive is implicitly the first authorization for placing the product on the 
market, taking into account that the product has been commercialized in Romania since 1998 and the 
authorization was renewed in 2005. 
 
The Court of Appeal of Bucharest allowed the appeal entered by OSIM against the Civil 
Decision no. 1087/A/19.10.2010 given by the Law Court of Bucharest, changed the attacked decision 
in whole as to the rejection of the appeal brought before the Law Court of Bucharest as unfounded. It 
consequently maintained the Decision of the OSIM Board of Appeal No. 12/25.02.2010 to refuse the 
SPC application c2007-073. The decision is irrevocable. Up to now, said decision has not been 
drafted yet. 
 
Conclusions (Author’s opinion) 
The cases presented above represent, in our opinion, five identically similar cases having as a 
subject-matter the application for the grant, in Romania, of SPCs in the transitional six month-period 
counting from the date of 1 January 2007, the date of Romania’s accession to the European Union. 
The legal ground invoked therefore is represented by Article 3 and Article 19 a (I) of the Regulation. 
In each of said cases, the product (the active substance) is protected in Romania by a patent in force, 
it has not already been the subject of a certificate, and the medicament containing the respective 
active substance was granted, after the date of 1 January 2000, a valid market authorization in 
accordance with the Directive 65/65/EEC. However, each of said medicaments had been authorized 
to be placed on the market, in Romania, before the date of 1 January 2000, by registration certificates 
which, on the date of their issuance, represented the legal way to place a medicament on the market. 
All said medicaments had a first authorization to be placed on the Community market, which was 
therefore obtained in accordance with the administrative procedure provided for by the Directive 
65/65/EEC, the date of which was earlier than the date on which the Registration Certificates were 
obtained in Romania. 
 
A synoptic summary of the market authorizations for the five cases is shown below: 
 
Medicament  Date of first 
authorization to place 
it on the market in the 
Community 
Date of the first 
Registration 
Certificate in 
Romania 
Date of the market 
authorization in 
Romania, in 
accordance with the 
Directive 65/65/EEC 
Humalog (Insulin 
Lispro) 
30.04.1996 (EMEA)  1996, 1997, 1998  2003 
Arimidex 
(Anastrozole) 
11.08.1995 27.05.1999 2006 Bucura Ionescu 1149 
Zyprexa (Olanzapine)  27.09.1996  1997  2001 
Atacand (Candesartan 
cilexetil) 
29.04.1997 (GB)  1998  2006 
Aricept (Donepezil)  14.02.1997 (GB)  14.01.1998  2005 
 
All said SPC applications were refused by the Examination Board of OSIM, as well as, 
following the applicant’s appeal, by the Board of Appeal, on the ground that the market 
authorizations granted in Romania according to the administrative procedures provided for by the 
Directive 65/65/EEC were not the first authorizations to place the products on the market, relying on 
the legal ground of their failure to cumulatively comply with the provisions of Article 3 (b) and (d) 
and Article 19 a (I) of the Regulation, and Article 20 (j) of the codified version of the Regulation, 
respectively. In each of said cases, the Chairman of the OSIM Board of Appeal expressed a 
dissenting opinion, arguing that “the phrase “first authorization to place a product on the market as 
a medicinal product” should be interpreted as the authorization granted in accordance with the 
Directive 65/65/EEC. In order to obtain the authorization, the patent owner had to comply with the 
entire procedure provided for by the Directive, in the case of a previously granted certificate the 
reauthorization being more than a simple renewal.”  
 
All the decisions of the OSIM Board of Appeal, as to reject the appeal, were appealed against 
by the applicant, and the Law Court of Bucharest allowed the appeals, the statements of reasons in all 
said cases being very similar. In brief, the Court retains that the problem submitted for trial is to 
establish if the Registration Certificates granted by the Ministry of Health before the date of 1 
January 2000, represent or not the first authorizations to place the product on the market, referred to 
under Article 3 (d) of the Regulation, as related to Article 3 (b) of the same Regulation and the 
harmonization of the Romanian legislation with the Directive 65/65/EEC. Because these certificates 
were not granted following a procedure pursuant to the Directive 65/65/EEC and do not comply with 
the conditions of Article 3 (b) and (d) of the Regulation, they cannot represent a valid authorization 
for placing the product on the market as a medicinal product and, thus, they are not deemed to be the 
first authorizations for placing the product on the market. The Court also finds that a medicament that 
has not been authorized pursuant to the Community law cannot be introduced onto the market of a 
Member State, and there are no provisions in the Directive 65/65/EEC to stipulate the possibility of 
such derogations to allow that the mere introduction onto the market, even during several years, of a 
medicament which was not the subject of a market authorization issued in accordance with the 
Community law, could replace such an authorization. 
In conclusion, the Court finds that the decision appealed against was made with the 
misinterpretation of the legal provisions and OSIM is ordered to grant the SPC. 
Whilst in the case Humalog, the decision of the Court remained final and irrevocable by lack 
of appeal, in the other cases the Civil Decisions of the Law Court of Bucharest were further appealed 
against by OSIM before the Court of Appeal of Bucharest. 
The further appeal relied on the consideration that, in ruling the appeal brought against the 
OSIM Board of Appeal, the Court misinterpreted the provisions of Article 3 and Article 19 a (I) of 
the Regulation. Having in view that, under Article 267 of the Treaty on the Functioning of the 
European Union (former Article 234 EC), the mission of ensuring application, interpretation and 
enforcement of Community law throughout the EU is incumbent on the European Court of Justice, 
OSIM found necessary that reference should be made to the ECJ for preliminary ruling.  
 
Although in two cases, i.e. Anastrozole and Olanzapine, there were applications for 
intervention in favour of the respondent OSIM, which claimed that the Court of Appeal should refer 
certain questions to the ECJ for preliminary ruling, the Court of Appeal did not find necessary to 1150  Challenges of the Knowledge Society. Legal sciences 
suspend the trial and refer for preliminary ruling and dismissed the OSIM appeal as unfounded. The 
legal provisions discussed were Article 2, Article 3 and Article 19 (I) of the Regulation. 
Court of Appeal and, consequently, the Decision No. 12/25.02.2010 of the Board of Appeal 
as to refuse the SPC application c2007-073 was maintained. This decision is irrevocable.  
Before upholding our opinion concerning the five cases, it is worth mentioning that the 
wrongful application of Article 3 (b) and (d) and Article 19 a (l) represents the legal ground of the 
decision to refuse the applications, and of the appeals and further appeals, as well.  
We will analyze in the first place the provisions of Article 3 of the Regulation: Conditions for 
obtaining a supplementary protection certificate. 
In our opinion, the reasoning of the interpretation of this article, reasoning on which the 
arguments leading to the decisions to grant four SPC of the five presented cases are based, is wrong. 
In fact, it represents a "reversal of premise"; in other words, if an authorization for placing a 
medicament on the market does not comply with the Directive 65/65/EEC, it cannot be deemed to be 
the first market authorization referred to under Article 3 (d) of the Regulation. Consequently, in all 
the five cases, the arguments are based on evidence proving that the Registration Certificates issued 
before the year 2000 do not comply with the requirements imposed to the market authorizations 
issued in accordance with the Directive, hence, they cannot be considered to be first authorizations to 
place the medicaments on the market, in Romania. It cannot be denied that the Registration 
Certificates were not based on the entire procedure provided for by the Directive, however, they 
represented the legal acts authorizing the presence of medicaments on the market, under the 
legislation in force in Romania. In some cases, the argument invoked in order not to take into account 
the Registration Certificates was that, for being granted a market authorization after the date of 1 
January 2000, i.e. in accordance with the Directive, the patent owner had to follow additional 
authorization procedures, not required on the date of the issuance of the Registration Certificates. 
This incurred important financial efforts for research, so that, if the Registration Certificates are 
deemed to be the first authorizations for placing the product on the market, the recital 4 of the 
preamble of the Regulation is not complied with. The recital 4 provides as follows: "Whereas at the 
moment the period that elapses between the filing of an application for a patent for a new medicinal 
product and authorization to place the medicinal product on the market makes the period of effective 
protection under the patent insufficient to cover the investment put into the research". In other words, 
the investment made with a view to obtaining authorization in accordance with the Directive 
65/65/EEC is not covered and this is why the grant of the SPCs is justified. Obviously, all these 
arguments are worthless, and so is any piece of evidence brought before the Court for proving that 
the Registration Certificates were not in accordance with the Directive. The synoptic table presented 
above shows clearly that all these Registration Certificates were issued in Romania subsequently to 
the market authorizations obtained in the Community. Hence, on the date on which the Certificates 
were applied for in Romania, the patent owners had already passed the exigency tests imposed by the 
Directive, the research necessary for completing the authorization file was already done, so that no 
further investment and effort were necessary for obtaining the market authorizations after the year 
2000. At the same time, one purpose of the Regulation was to compensate the time needed for 
making the tests imposed by the Directive, which diminishes the actual duration of the protection 
given by the patent. If all the tests required by the Directive had already been performed in order to 
obtain the first market authorizations in the Community, prior to the issuance of the Registration 
Certificates, is the compensation given through the SPC for having obtained the authorizations for 
placing the product on the market in Romania still justifiable? Of course not. 
Moreover, in the majority of the presented cases, the market authorizations obtained after the 
year 2000 are in fact re-authorizations of the Registration Certificates. In a literal interpretation, the 
meaning of the word re-authorization leads to the idea of successive authorizations: an authorization 
existing at a certain moment is subsequently authorized again. In other words, the Registration 
Certificates may not be ignored. Moreover, they may not be ignored even when certain medicaments, Bucura Ionescu 1151 
e.g. Zyprexa, existed on the market within the period 2000-2001, based on the Registration 
Certificates, without any obligation to withdraw the same. As a matter of fact, in the above 
mentioned period of time, the authorization regime based on Registration Certificates co-existed, in 
Romania, with the regime based on market authorizations in accordance with the Directive. 
Our interpretation of Article 3 (b) and (d) of the Regulation is that the authorization obtained 
in accordance with the Directive 65/65/EEC should be understood as the first authorization having 
made possible for the product to be placed on the market as a medicinal product, and not that only 
the first authorization obtained in accordance with the Directive is the first authorization for placing 
the product on the market, as the applicants argued in all the presented cases. In other words, the 
concept of "market authorization" does not automatically include the conformity with the Directive, 
but, on the contrary, within the meaning of the Regulation, the conformity with the Directive is the 
condition that the first authorization must comply with for an SPC to be granted. 
As far as the case C-127/00 Hassle AB vs Ratiopharm GmbH, invoked by the SPC applicants, 
is concerned, we concur with the opinion expressed each time by OSIM on the erroneous decision of 
the Court as to admit said case-law. The subject of this case and the legal issue settled by the ECJ are 
different from the cases in Romania, because the problem raised by the case C-127/00 is whether an 
authorization concerning the price of a medicament can be considered to be a first authorization to 
place a product on the market within the meaning of the Regulation
25. In support of our assertion, we 
further quote: "In this context, the Community Court admitted that the phrase "first authorization for 
placing a product on the market" refers to the "first authorization applied for in accordance with the 
provisions concerning the medicinal products, within the meaning of the Directive 65/65/EEC of 26 
January 1965". In other words, it is the first authorization having the same nature as the authorization 
provided by the Directive 65/65/EEC, namely an authorization required, according to the legislation 
on medicinal products, for placing the product on the market (Note: The authorization provides for 
tests to be carried out with a view to completing pharmaceutical, pre-clinical pharmacological, pre-
clinical toxicological and clinical files), which is different from other authorizations concerning 
pricing or price reimbursement in medicaments.
26 
Regarding Article 19 a (l), it is noticeable that the wording of this article referring to Romania 
is different in comparison with the provisions referring to the other Member States accessed after 
2004, whereas the second sentence thereof refers to Article 7 (1) which, in its turn, refers to the 
market authorization obtained in accordance with the Directive 65/65/EEC. Consequently, the 
interpretation given invariably by the applicant for an SPC was that only the authorization obtained 
in Romania after 1 January 2000, as the only one granted in accordance with the Directive, 
represented in fact the first authorization for placing the product on the market, in Romania, as a 
medicinal product.  
As regards the interpretation of Article 19 of the Regulation, we consider that, in both its letter 
and spirit, the Regulation does not aim to remove or annul the effects produced by the authorizations 
issued before the date of 1 January 2000 (referred to under Article 19 a (l) of the Regulation) or to 
deny the obvious fact that the medicaments have been placed on the market, even authorized in 
accordance with the national legislation in force on that date, which was not fully harmonized with 
the Directive. The purpose of the Regulation was to provide for uniform solutions at the Community 
                                                 
25 The relevant paragraph of the case C-127/00 reads as follows: 
“So far as concerns medicinal products for human use, the concept of ‘first authorisation to place ... on the 
market ... in the Community’ in Article 19(1) of Regulation No 1768/92 refers solely to the first authorisation required 
under provisions on medicinal products […] granted in any of the 
Member States, and does not therefore refer to authorizations required under legislation on pricing of or 
reimbursement for medicinal products.” 
26 Document drafted by the law firm Stoica & Asociaţii and filed with OSIM on 9 June 2011, in support of the 
further appeal lodged by OSIM against the Decision No. 1087A of 19.10.2010 of the Law Court of Bucharest in the 
case Donepezil, for SC Labormed Pharma SA, page 4. 1152  Challenges of the Knowledge Society. Legal sciences 
level, in order to prevent the risk of displacement of the research centres in Member States offering 
better protection, and this has been related to Romania since 1 January 2000. If the authorizations 
legally granted in Romania prior to 1 January 2000 could not be considered to be the first 
authorizations to place certain products on the market, because they are not in accordance with the 
Directive, the reference date mentioned in Article 19 a (l) (i.e. 1 January 2000) would be completely 
useless, as all the products authorized to be placed on the market after this date would automatically 
be eligible for the grant of an SPC, provided that market authorizations in accordance with the 
Directive were only obtained after this date, and the provision would become redundant. 
Special attention has been given throughout this paper to the case Anastrozole (medicament 
Arimidex) and the application for accessory intervention filed by Teva, because we completely agree 
with the arguments brought by the intervener in support of the opinion that a product authorized to be 
placed on the market for the first time in Romania before the date of 1 January 2000, without having 
previously been subject to the administrative procedure provided for by the Directive 65/65/EEC, is 
not eligible for the grant of an SPC under the provisions of the Regulation, as it does not comply with 
the scope of Article 2. It is only on the occasion of the applications for intervention that this article of 
great importance for the correct application of the Regulation is invoked for the first time. 
Unfortunately, OSIM has never had in view this article, its attention being exclusively focused on the 
legal ground invoked by the applicant in the applications for the grant of an SPC: Article3 and 
Article 19 a (I). And, as we have argued above, regarding the products eligible for the grant of an 
SPC, Article 2 sets out two conditions to be complied with: the product should be protected by a 
basic patent and subject to authorization procedure in accordance with the Directive before its being 
placed on the market. The difference between the provisions of Article 2 and of Article 3 (a) and (b) 
consists in that the scope of Article 2 excludes those products placed on the market without an 
authorization in accordance with the Directive 65/65/EEC. However, we cannot disagree with the 
fact that invoking Article 2 for the first time before the Court of Appeal contravenes the principle of 
double jurisdiction. Moreover, if the grant of SCP were possible for products placed on the market 
based on other authorizations than those granted in accordance with the Directive, in certain cases the 
exclusivity period would exceed the total limit of 15 years from the date of the first authorization in 
the Community, referred to in the eighth recital of the preamble of the Regulation (it is, for example, 
the case of the product Donepezil): “The duration of the protection granted by the certificate should 
be such as to provide adequate effective protection; for this purpose, the holder of both a patent and 
a certificate should be able to enjoy an overall maximum of fifteen years of exclusivity from the time 
the medicinal product in question first obtains authorization to be placed on the market in the 
Community”  
In support of this argument we also rely on the case C-195/09 Synthon BV vs Merz Pharma 
GmbH & Co KG in which the European Court of Justice ruled, on 28 July 2011
27, on the referrals 
concerning the interpretation of Article 2, 13 and 19 of the Regulation. The case is worth being 
briefly presented since, in our opinion, this case-law is also applicable to the previously presented 
cases and could lead, for the cases still pending before the Law Court of Bucharest and the Court of 
Appeal
28, to be ruled differently than the previous cases. Besides, it was also invoked in the case 
Anastrozole. It results from the case file that the active substance named memantine has been 
commercialized on the German market as the medicament Akatinol of the pharmaceutical company 
Merz before the date of 1 September 1976, based on a German regulation of 1961 which obviously 
did not comply with the provisions of the subsequent Directive 65/65/EEC. On 13 November 2002, 
the company filed in UK an application for the grant of an SPC for memantine, where an 
authorization granted in the UK in 2002 was mentioned as the first authorization for placing the 
                                                 
27 http://eur-lex.europa.eu, OJ of 08.10.2011 
28 On the date of drafting this paper, the ruling of the Court of Appeal on the appeal entered by OSIM in the 
case Sildenafil is still pending pronouncement. Bucura Ionescu 1153 
product on the market, without mentioning the market authorization obtained in Germany. The SPC 
was granted by the UK Patent Office. By the action brought before the High Court of Justice (Patent 
Court), the generic medicaments company Synthon claimed that the said SPC should be declared 
invalid or the duration of its protection should be fixed at zero. Having doubts relating to the scope of 
the Regulation and to the interpretation to be given to the concept of "first authorization to be placed 
on the market in the Community", the High Court of Justice specialized in the field of patents 
decided to suspend the judgment of the case to refer a series of question to the ECJ for preliminary 
ruling. The third of these questions is, in our opinion, relevant for the cases of Romania. 
"Is a product which is authorised to be placed on the market for the first time in the EEC 
without going through the administrative procedure laid down in [Directive 65/65] within the scope 
of [Regulation No 1768/92] as defined by Article 2?"  
The Court interpretation to the scope of the Regulation was that " for the purposes of 
obtaining an SPC, the product concerned must be protected by a valid patent in the national territory 
and it must have been subject, prior to being placed on the market as a medicinal product, to an 
administrative authorisation procedure as laid down in Directive 65/65."  
This interpretation is confirmed by the purpose of the Regulation. As it is apparent from the 
first to fourth recitals in the preamble to Regulation No. 1768/92, in order to ensure sufficient 
protection to encourage pharmaceutical research, that regulation seeks, through the creation of an 
SPC for medicinal products that were granted marketing authorisation, to make up for the fact that 
the period of effective protection under the patent is insufficient to cover the investment put into the 
research, given the period that elapses between the filing of an application for a patent for a new 
medicinal product and the authorisation to place that product on the market. It would be contrary to 
that objective of offsetting the time taken to obtain a marketing authorisation – which requires long 
and demanding testing of the safety and efficacy of the medicinal product concerned – if an SPC, 
which amounts to an extension of exclusivity, could be granted for a product which has already been 
sold on the Community market as a medicinal product before being subject to an administrative 
authorisation procedure as laid down in Directive 65/65. 
The conclusion of the Court was that such a medicinal product is not within the scope of 
Regulation No 1768/92 and may not, therefore, be the subject of an SPC. 
We find that this case is similar with the previously presented cases and it must be noticed 
that a court having such a prodigious experience in the field of patents and SPC like the High Court 
of Justice (Patent Court) in the UK referred for preliminary ruling by the ECJ, in 2009, questions 
concerning the interpretation of the Regulation in force in the Community since 1992, in order for it 
to meet the essential condition for the Community legislative acts, namely to provide for uniform 
solutions at the Community level. That is why we cannot agree with the fact that, although in 
Romania there is no case-law in the SPC field and, for the discussed cases, various diverging 
interpretations were given to the Regulation, the Romanian courts refused the referral for preliminary 
ruling by the ECJ and contradictorily ruled in identically similar cases. 
We hereby express our hope that this paper could contribute, to a certain extent, to create an 
overview of SPC cases which raised special problems of interpretation of a Community regulation, 
as well as to deliver judgments based, on the one hand, on the Community case-law, and, on the 
other hand, to ensure the observance of the constitutional principle of the free trade for those 
medicaments producers whose right to the free exploitation of the patented technical solution could 
be abusively restricted.  
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